Ascendis scores hard-fought FDA nod for hormone replacement therapy Yorvipath

[cafead]

via Ascendis Pharma should be well prepared for the U.S. launch of its hormone replacement therapy for hypoparathyroidism, which was approved on Friday by the FDA.

article source